Item 7.01 - Regulation FD Disclosure.

On November 7, 2022, Amicus Therapeutics, Inc. (the "Company") issued a press release announcing an EU regulatory update for AT-GAA. A copy of this press release is attached hereto as Exhibit 99.1. In connection with this announcement, the Company also updated its presentation materials which have been attached hereto as Exhibit 99.2. Both exhibits are incorporated herein by reference.

The information in this Item 7.01, including Exhibits 99.1 and 99.2, are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Act, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into any registration statement or other document pursuant to the Act.

Item 9.01 Financial Statements and Exhibits





(d) Exhibits:



     Exhibit No.                            Description
         99.1       Press Release dated November 7, 2022
         99.2       November 7, 2022 Presentation Materials
                  Cover Page Interactive Data File (embedded within the Inline
         104      XBRL document)

© Edgar Online, source Glimpses